49,855 Shares in Royalty Pharma PLC $RPRX Acquired by Partners Group Holding AG

Key Points

• Partners Group Holding AG opened a new position in Royalty Pharma, buying 49,855 shares valued at about $1.93 million in the fourth quarter.
• Wall Street sentiment remains constructive: several analysts raised price targets, and the stock now has a consensus Buy rating with a target price of $53.71.
• Royalty Pharma reported EPS of $1.30 for the latest quarter, beating estimates, and it also declared a quarterly dividend of $0.235 per share payable June 10.

Partners Group Holding AG bought a new position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 49,855 shares of the biopharmaceutical company's stock, valued at approximately $1,926,000.

Several other large investors have also recently added to or reduced their stakes in RPRX. Smartleaf Asset Management LLC grew its holdings in Royalty Pharma by 868.1% during the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 790 shares in the last quarter. Private Trust Co. NA grew its holdings in Royalty Pharma by 52.9% during the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 288 shares in the last quarter. Larson Financial Group LLC grew its holdings in Royalty Pharma by 31.9% during the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 306 shares in the last quarter. Fifth Third Bancorp grew its holdings in Royalty Pharma by 16.9% during the 3rd quarter. Fifth Third Bancorp now owns 2,499 shares of the biopharmaceutical company's stock worth $88,000 after acquiring an additional 362 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Royalty Pharma during the 3rd quarter worth approximately $100,000. 54.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on RPRX shares. Weiss Ratings cut shares of Royalty Pharma from a "buy (b)" rating to a "buy (b-)" rating in a report on Friday. Morgan Stanley boosted their price target on shares of Royalty Pharma from $61.00 to $63.00 and gave the stock an "overweight" rating in a report on Friday, April 10th. Citigroup boosted their price target on shares of Royalty Pharma from $50.00 to $66.00 and gave the stock a "buy" rating in a report on Thursday, May 7th. TD Cowen reiterated a "buy" rating on shares of Royalty Pharma in a report on Friday, February 27th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Royalty Pharma from $50.00 to $58.00 and gave the stock an "overweight" rating in a report on Thursday, May 7th. Seven research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $53.71.

Royalty Pharma Trading Up 0.7%

Shares of Royalty Pharma stock opened at $52.41 on Wednesday. The company has a fifty day simple moving average of $48.58 and a 200-day simple moving average of $43.61. Royalty Pharma PLC has a 12-month low of $32.15 and a 12-month high of $53.47. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86. The stock has a market cap of $30.18 billion, a price-to-earnings ratio of 35.65, a PEG ratio of 1.43 and a beta of 0.40.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.08. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. The business had revenue of $631.00 million during the quarter, compared to analysts' expectations of $881.69 million. On average, equities analysts forecast that Royalty Pharma PLC will post 5.05 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a $0.235 dividend. The ex-dividend date is Friday, May 15th. This represents a $0.94 annualized dividend and a dividend yield of 1.8%. Royalty Pharma's dividend payout ratio is presently 63.95%.

Insider Activity

In other news, Director Gregory Norden sold 3,045 shares of the company's stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $53.00, for a total value of $161,385.00. Following the completion of the transaction, the director owned 191,803 shares in the company, valued at approximately $10,165,559. This represents a 1.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Terrance P. Coyne sold 34,791 shares of the company's stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $49.78, for a total transaction of $1,731,895.98. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 155,893 shares of company stock worth $7,512,360. Corporate insiders own 18.84% of the company's stock.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.

Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Royalty Pharma PLC (NASDAQ:RPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.